Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)

The National Institutes of Health (NIH), within the U.S. Department of Health and Human Services, is offering a cooperative agreement funding opportunity titled the Continuation of the Cardiovascular Repository for Type 1 Diabetes (CARE-T1D) Consortium U01. This initiative builds upon an existing research consortium established to address critical gaps in understanding cardiovascular disease (CVD) among individuals with type 1 diabetes (T1D). NIH, as a leading federal biomedical research agency, supports large-scale collaborative research efforts to advance scientific knowledge and improve public health outcomes. This funding opportunity is aligned with the Special Diabetes Program, which focuses on advancing prevention, treatment, and potential cures for T1D and its complications. The primary purpose of this funding opportunity is to continue and expand interdisciplinary and collaborative research efforts that investigate the mechanisms underlying cardiovascular complications in individuals with T1D. Cardiovascular disease remains the leading cause of mortality in this population, with conditions such as atherosclerosis, cardiomyopathy, endothelial dysfunction, and cardiac autonomic neuropathy contributing significantly to reduced life expectancy. Despite improvements in managing traditional risk factors like blood glucose, blood pressure, and cholesterol, residual cardiovascular risk persists, highlighting the need for deeper scientific investigation and novel therapeutic approaches. Funding under this opportunity will support research projects that contribute to the CARE-T1D consortium’s objectives, including data sharing, repository development, and collaborative analysis. The cooperative agreement mechanism (U01) indicates substantial involvement from NIH program staff in project coordination and oversight. Funds may be used for a range of research-related activities, including data collection, analysis, infrastructure development, and collaboration across institutions. Clinical trials are not allowed under this specific opportunity, ensuring that funded projects remain focused on observational, mechanistic, or preclinical research. Eligibility for this opportunity is broad and includes a wide range of domestic entities such as state and local governments, nonprofit organizations with or without 501(c)(3) status, institutions of higher education (both public and private), small businesses, and tribal organizations. However, non-U.S. entities are not eligible to apply directly, although foreign components within U.S.-based organizations may be included as part of a project. Applicants are encouraged to consult the full Notice of Funding Opportunity (NOFO) for detailed eligibility requirements and definitions. The application process requires submission through Grants.gov, following standard NIH procedures. While no pre-application such as a letter of intent is explicitly required in the provided synopsis, applicants must prepare comprehensive research proposals that align with NIH guidelines. These typically include detailed research plans, budgets, biosketches, and institutional assurances. Applications will undergo peer review based on scientific merit, significance, innovation, approach, and investigator qualifications, consistent with NIH review criteria. The opportunity was posted on June 4, 2026, with an application deadline of March 10, 2027. Approximately $6,000,000 in total program funding is expected to be available, with up to eight awards anticipated. Individual awards may reach up to $500,000. There is no cost-sharing or matching requirement for this program. Awards are expected to support multi-year research efforts, although the exact project period is specified in the full NOFO. As this is part of an ongoing consortium effort, similar opportunities may be issued in future cycles, suggesting a recurring funding pattern aligned with NIH program priorities.